NEW APPROACHES TO BRAIN TUMOR THERAPY CNS CONSORTIUM

这项建议的主要长期目标是改善 成人原发性脑肿瘤的治疗结果。这将是 通过促进I期和II期临床评价， 新的药物，生物学方法和给药途径， 治疗中枢神经系统（CNS）原发性恶性肿瘤 通过建立名为“新方法， 脑肿瘤治疗（NABTT）。“这个财团是专门为 联合收割机，集中七个公司的经验、资源和能力 杰出的医疗机构（约翰霍普金斯大学，布朗 大学、哥伦比亚大学、克利夫兰诊所、马萨诸塞州 西北大学[芝加哥]总医院和 宾夕法尼亚州）承担原发性脑肿瘤。为了实现这一目标， 财团将依靠的特殊优势和能力，休息 在每个参与机构和联合体内部， 整体参与的机构有（1）大量的成年人 原发性脑肿瘤患者，（2）专家多学科临床 （3）广泛的临床和医疗服务， 实验室资源，（4）正在进行的高质量， 临床相关、同行评审和NIH资助的临床和实验室 脑肿瘤研究项目，（5）国家认可的专业知识， 肿瘤学、药理学、新药开发、I期和II期临床 试验，神经外科和神经病理学（6）在以下方面的广泛专业知识 统计、数据管理和多机构协调 研究，和（7）卓越的声誉，在临床护理 与研究该联盟通过认可这些优势， 章程，明确的组织结构，并强调 研究设计、方案制定、质量控制、研究监查， 数据管理和分析。 该提案的第二个长期目标是利用这一点， 共享人类脑肿瘤标本以及其他临床 和实验室数据进行额外的研究有关（1） 原发性脑肿瘤的基础生物学，（2）新的神经药理学 治疗原发性脑肿瘤，（3）改善护理和质量 成年原发性脑肿瘤患者的生命周期。这一目标将是 利用各个机构和NABTT的优势 CNS Consortium，如上所述。

The primary long-term objective of this proposal is to improve the therapeutic outcome for adults with primary brain tumors. This will be accomplished by fostering Phase I and II clinical evaluations of promising new agents, biologic approaches, and routes of administration in the treatment of primary malignancies of the central nervous system (CNS) through the establishment of the CNS consortium titled "New Approaches to Brain Tumor Therapy (NABTT)." This consortium is specifically designed to combine and focus the experience, resources, and capabilities of seven outstanding medical institutions (The Johns Hopkins University, Brown University, Columbia University, The Cleveland Clinic, The Massachusetts General Hospital, Northwestern University [Chicago], and The University of Pennsylvania) to bear on primary brain tumors. To meet this objective, the consortium will rely on the special strengths and abilities that rest within each participating institution and within the consortium as a whole. The participating institutions have (1) a large number of adult patients with primary brain tumors, (2) expert multidisciplinary clinical teams in place to care for these patients, (3) extensive clinical and laboratory resources, (4) a striking number of ongoing high quality, clinically relevant, peer-reviewed and NIH funded clinical and laboratory brain tumor research projects, (5) nationally recognized expertise in oncology, pharmacology, new drug development, Phase I and II clinical trials, neurosurgery, and neuropathology (6) extensive expertise in statistics, data management, and the coordination of multi-institutional studies, and (7) exceptional reputations for excellence in clinical care and research. The consortium adds to these strengths by endorsed constitution, well-defined organizational structure, and emphasis on research design, protocol development, quality control, study monitoring, and data management and analysis. The secondary long-term objective of this proposal is to utilize this consortium to share human brain tumor specimens as well as other clinical and laboratory data to conduct additional research pertaining to (1) the basic biology of primary brain tumors, (2) the neuropharmacology of new therapies for primary brain tumors, and (3) improving the care and quality of life of adults with primary brain tumors. This objective will be reached using the strengths of the individual institutions and the NABTT CNS Consortium which are outlined above.